1. A pharmaceutical combination for use in treating a patient with type 2 diabetes, type 2 diabetes where unsatisfactorily controlled by at least one oral antidiabetic drug comprising (a) desProEksendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof, (b) insulin glargine and / or a pharmaceutically acceptable salt thereof, and (c) metformin and / or a pharmaceutically acceptable salt thereof, where the treatment of a patient with type 2 diabetes comprising the steps of: (i) administration of the compounds (b) and (c ) for at least 4 weeks, and (ii) the continuation of treatment by administration of the compounds (a), (b) and (c), wherein the amount of compound (b), to be administered in steps (i) and / or (ii) is adjusted so as to achieve or at least approach the preset level of fasting plasma glucose and / or a predetermined self-monitoring of plasma glucose levels, and wherein at the beginning of step (i) the patient has a concentration of glucose in plasma 2 hours after administration food at least 12 mmol / L.2. Pharmaceutical combination according to claim. 1, wherein step (i) comprises introducing the compounds (b) and (c) for at least 4 weeks, at least eight weeks, at least 12 weeks, or at least 16 nedel.3. Pharmaceutical combination according to claim. 2, wherein the step (i) comprises the administration for at least about 12 nedel.4. Pharmaceutical combination according to Claim. 1 or 2, wherein step (i) is performed, provided that the compound (a) is not vvoditsya.5. Pharmaceutical combination according to Claim. 1 or 2, wherein steps (i) and / or (ii) further comprise administering tiazolidinediona.6. Pharmaceutical combination according to Claim. 1 or 2, wherein the introduction in steps (i) and1. Фармацевтическая комбинация для применения при лечении пациента с диабетом 2 типа, где диабет 2 типа неудовлетворительно контролируется посредством по меньшей мере одного перорального противодиабетического лекарственного средства, содержащая(
